© 2011

Pulmonary Involvement in Patients with Hematological Malignancies

  • Elie Azoulay

Table of contents

  1. Front Matter
    Pages i-xix
  2. Preamble and Introduction

  3. Epidemiology

  4. Diagnostic Strategy in HM Patients

    1. Front Matter
      Pages 121-121
    2. Cédric de Bazelaire, Raphael Calmon, Marion Chapelier, Amélie Pluvinage, Eric de Kerviler
      Pages 155-173
    3. Laurent Camous, Virginie Lemiale, Achille Kouatchet, David Schnell, Sandra de Miranda, Élie Azoulay
      Pages 175-189
    4. Michael G. Alexandrakis, Paschalis Steiropoulos, Demosthenes Bouros
      Pages 191-208

About this book


The number of patients treated for hematological malignancies is increasing steadily. To obtain the highest possible cure rates, aggressive treatments have been introduced, including high-dose chemotherapy, stem cell transplantation, and targeted therapies. As a result, overall and disease-free survival rates have improved substantially; however, this has been achieved at the price of life-threatening toxic and infectious complications that chiefly target the lung. This book provides clinicians caring for patients with hematological malignancies with detailed, up-to-date information on all relevant aspects of pulmonary involvement. Individual sections are devoted to epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure. Each of these sections contains a number of chapters, all written by leading international experts. In addition, the reader’s attention is drawn to important "pearls" relating to each condition.


Bone Marrow Transplantation Bronchoscopy and BAL Drug Related Pulmonary Toxicity Neutropenia Pneumocystis

Editors and affiliations

  • Elie Azoulay
    • 1
  1. 1.Service de Réanimation MédicaleHôpital Saint LouisParisFrance

About the editors

Dr Élie Azoulay is the Assistant Director of the Medical ICU at the Saint-Louis Teaching Hospital, Paris, France. He is a professor of medicine at the Denis Diderot Paris 7 University. From his background as a pulmonologist, Dr Azoulay developed a strong research focus on acute respiratory failure in immunocompromized patients. His PhD work was on respiratory physiology in an experimental model of cancer chemotherapy-related pulmonary toxicity. He has several published clinical research studies on acute respiratory failure in hematology and oncology patients. Also, Dr Azoulay leads a collaborative multicenter group that has performed observational studies, large cohort studies, and randomized controlled trials in cancer patients with ARF. His second major field of interest in clinical research is communication with family members of ICU patients. He constituted a research group in 1997 (the French Famirea Study Group) to evaluate the ability of critical care clinicians to provide effective information to ICU patients and families. Several of his published studies investigated the burden of critical illness in relatives and in ICU clinicians. The group’s major aim is to identify targets for improvement and to test potential interventions in international RCTs in order to advance ICU practices in the field of information and communication. In addition to clinical and research activities, Dr Azoulay teaches pulmonary medicine, critical care medicine, and ethics at the Paris Medical School. He is also associate editor of Intensive Care Medicine, in the editorial board of the American Journal of respiratory and Critical Care medicine, and the chairman of the ethics section of the ESICM. Dr Azoulay is a member of the European board of Pfizer and Gilead.

Bibliographic information

Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology


From the reviews:

“This is a detailed, multiauthored review of infectious, inflammatory, and thromboembolic complications in patients with a variety of hematological cancers. … Practitioners with an interest in hematological malignancy and intensivists providing critical care resources for management of these patients are an appropriate audience for this work coming from an international panel of authors, the majority of whom are from France. … This unique book effectively reviews the current therapy, incidence, and outcomes for this complex patient group.” (David J. Dries, Doody’s Review Service, December, 2011)